$XBI $105.23 -5.50% %
Covid Updates
$NRXP +3.0% NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies. source
$HGEN -11.5% Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved. source
$BCEL -6.3% Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs. source
Pipeline Updates
$STRO -3.5% Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer source
$EGRX -1.6% Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin source
$CYDY -11.1% Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose. source
$ZSAN +0.8% Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose. source
$AVEO -13.7% NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma. source
$ANVS -9.2% Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401. source
$CUE -8.5% Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102. source
$ALRN -7.3% Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones. source
$LGVN +2.2% Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease. source
$EXEL -3.8% Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma. source
$LPCN -2.8% Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference. source
$EWTX +22.5% Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD). source
$VBIV -6.0% VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio. source
$JAZZ +0.1% Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia. source
$ATNM -7.3% Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy. source
$ORMP -8.3% Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins. source
$NTLA -9.0% Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases. source
$ALVR -1.7% FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation. source
$IFRX -3.0% InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa. source
$INFI -18.2% Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance. source
$COGT -0.7% Cogent Biosciences Provides 2022 Corporate Guidance. source
$BHVN -3.9% & $PFE +2.0% Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States. source
$MRNA -7.7% Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine. source
$ATHA +1.2% Athira Pharma Provides 2022 Pipeline Outlook. source
$BCYC -2.3% Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team. source
$CNTB -12.3% Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis. source
$PFE & +2.0% $BNTX -5.7% Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine. source
$MNKD -3.8% MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases. source
$IDYA -9.4% IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE™ Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform. source
$VRNA -1.4% Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset. source
$ENDP -3.2% Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution. source
Business Updates
$SPPI -11.2% Spectrum Pharmaceuticals Announces Strategic Restructuring. source
$AMRX -2.7% Amneal Acquires Saol Therapeutics’ Baclofen Franchise. source
Posted by FS/ER/JM
Comments